Nivolumab,Ipilimumab
BMS
['yervoy', 'opdivo', 'nivo', 'ipilimumab', 'nivolumab']
a study of neoadjuvant nivolumab (opdivo) and ipilimumab (yervoy) found that the immunotherapy combination led to striking responses in patients with mismatch repair-deficient #coloncancer. #esmo22 
OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals.